Abstract Background The Canadian government has committed to developing a national strategy for drugs for rare diseases starting in 2022. Considering this announcement. we conducted a comparative analysis to examine patient access to therapies for rare disease in Canada relative to Europe and the U. S. https://iguanasellers.shop/product-category/document-case/